PTCSC3 and prostate cancer: Prognostic data from 125 prostate cancer patients revealed that those in the PTCSC3 low-group had shorter survival times than the PTCSC3 high-group (HR = 3.13, 95% CI = 1.36–7.25, Log-rank P value = 0.01; Fig. 1c).